These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27687641)

  • 21. Q&A: Bernard Munos.
    Bender E
    Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
    [No Abstract]   [Full Text] [Related]  

  • 22. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.
    Liapikou A; Cillóniz C; Torres A
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1239-1248. PubMed ID: 28952384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry.
    Lavin BS
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S32-5. PubMed ID: 10654633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antibiotic resistance crisis, with a focus on the United States.
    Martens E; Demain AL
    J Antibiot (Tokyo); 2017 May; 70(5):520-526. PubMed ID: 28246379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the GAIN Act a turning point in new antibiotic discovery?
    Brown ED
    Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards new business models for R&D for novel antibiotics.
    So AD; Gupta N; Brahmachari SK; Chopra I; Munos B; Nathan C; Outterson K; Paccaud JP; Payne DJ; Peeling RW; Spigelman M; Weigelt J
    Drug Resist Updat; 2011 Apr; 14(2):88-94. PubMed ID: 21439891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Who will develop new antibacterial agents?
    Cole ST
    Philos Trans R Soc Lond B Biol Sci; 2014; 369(1645):20130430. PubMed ID: 24821916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novelty in the target landscape of the pharmaceutical industry.
    Agarwal P; Sanseau P; Cardon LR
    Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
    [No Abstract]   [Full Text] [Related]  

  • 29. Ian Tomlinson.
    Tomlinson I
    Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
    [No Abstract]   [Full Text] [Related]  

  • 30. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
    Barriere SL
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 33. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ
    Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is an "ideal" antibiotic? Discovery challenges and path forward.
    Singh SB; Young K; Silver LL
    Biochem Pharmacol; 2017 Jun; 133():63-73. PubMed ID: 28087253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges for the development of new treatments for severe asthma: a pharmaceutical perspective.
    Knowles RG
    Curr Pharm Des; 2011; 17(7):699-702. PubMed ID: 21406057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J
    BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
    [No Abstract]   [Full Text] [Related]  

  • 37. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel antibiotic treatment for skin and soft tissue infection.
    Dryden MS
    Curr Opin Infect Dis; 2014 Apr; 27(2):116-24. PubMed ID: 24504135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.